Cimed is about to inaugurate the largest drug factory in Latin America and, in addition to generating several job openings, the company plans to expand its presence in the national domestic market to 25%
The new Cimed Headquarters will take the company to the level of the largest pharmaceutical industry in Latin America, according to João Adibe Marques CEO of the company. According to the executive, in January of next year, a new medicine factory will be inaugurated, located in Pouso Alegre. The aim is to expand from 10 to 25% the share of the national domestic market, in addition to generating up to 500 job openings. The group also invested in space discovery in partnership with international institutions.
Read other related news
Largest drug factory in Latin America has 770 m²
The new Cimed unit has more than 770 m² of total area, which includes a drug factory, printing facilities and distribution center in São Sebastião da Bela Vista and Pouso Alegre, both in the south of Minas Gerais.
According to company information, expected revenue for this year is R$ 2,3 billion, 20% more than in 2020. Products sold by the company represent 10% of all medicines sold in the country.
In total, there are 450 million boxes sold per year, which leave the drug factory. According to the Cimed executive, the new factory, which aims to be the largest in Latin America, just needs certification to be inaugurated and create job openings. The headquarters will allow for a leap forward for the company, with total capacity expected for almost 25% of everything sold in the country.
Cimed promises to generate hundreds of job openings
Hiring to work at the largest drug factory in Latin America has already begun. According to Adibe, as the production lines receive certification, job vacancies will be generated for professionals in the region.
The group estimates to hire around 300 employees. In total, it should reach 500 jobs generated in the first year of operation, depending only on certifications.
CLICK HERE TO CHECK THE COMPANY'S VACANCY LIST
Cimed invests BRL 300 million to launch a Covid virus protein into space
A rocket launched last week took a protein from the Covid-19 virus into space through the Cimed X project. Investment in the project is approximately R$ 300 million. The international partnership for pharmaceutical research is aided and supported by the US space agency, NASA. According to the Cimed executive, the company is sponsoring this project along with several bodies.
The initiative is a pioneer among national companies in the sector. The rocket was launched with the aim of crystallizing the Covid 19 protein. The objective is to make discoveries outside Earth's orbit and develop research that will bring benefits to the world's population.
Another focus of the space project is regenerative medicine. According to Adibe, this is a long-term project, which needs to take between four and five years, and Cimed will use the space precisely to accelerate this process.
